| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 降血压类原料及中间体(元) | - | - | - | 1,436,898,263.00 | 743,642,607.54 |
| 抗凝血类原料药及中间体(元) | - | - | - | 270,825,944.75 | 158,220,586.93 |
| 降血糖类原料药及中间体(元) | - | - | - | 272,926,252.37 | - |
| 降血脂类原料药及中间体(元) | - | - | - | 99,621,978.40 | - |
| 抗哮喘类原料及中间体(元) | - | - | - | 203,592,050.78 | - |
| 制剂(元) | 280,144,121.55 | 417,997,588.19 | 179,233,347.65 | 254,761,203.94 | - |
| CMO(元) | 103,956,936.15 | 391,898,566.41 | 251,162,781.51 | - | - |
| 仿制药原料药及中间体(元) | 1,373,010,674.86 | 2,221,878,359.64 | 1,131,315,045.91 | - | - |
| 高纯溶剂(元) | 207,000,793.91 | - | - | - | - |
| 其他(元) | 46,612,765.23 | 29,360,879.53 | 5,721,349.18 | 92,182,550.16 | - |
| 营业成本(元) | |||||
| 降血压类原料及中间体(元) | - | - | - | 933,859,621.41 | 480,961,621.19 |
| 抗凝血类原料药及中间体(元) | - | - | - | 140,671,957.71 | 80,135,575.44 |
| 降血糖类原料药及中间体(元) | - | - | - | 187,102,689.48 | - |
| 降血脂类原料药及中间体(元) | - | - | - | - | - |
| 抗哮喘类原料及中间体(元) | - | - | - | - | - |
| 制剂(元) | 133,830,379.31 | 185,546,923.01 | 74,934,513.83 | - | - |
| CMO(元) | 55,103,222.61 | 190,953,096.71 | 114,679,924.81 | - | - |
| 仿制药原料药及中间体(元) | 997,352,022.16 | 1,515,739,401.21 | 768,657,424.96 | - | - |
| 高纯溶剂(元) | 173,065,061.85 | - | - | - | - |
| 其他(元) | 45,375,441.44 | 33,416,017.79 | 9,859,611.54 | - | - |
| 毛利(元) | |||||
| 降血压类原料及中间体(元) | - | - | - | 503,038,641.59 | 262,680,986.35 |
| 抗凝血类原料药及中间体(元) | - | - | - | 130,153,987.04 | 78,085,011.49 |
| 降血糖类原料药及中间体(元) | - | - | - | 85,823,562.89 | - |
| 降血脂类原料药及中间体(元) | - | - | - | - | - |
| 抗哮喘类原料及中间体(元) | - | - | - | - | - |
| 制剂(元) | 146,313,742.24 | 232,450,665.18 | 104,298,833.82 | - | - |
| CMO(元) | 48,853,713.54 | 200,945,469.70 | 136,482,856.70 | - | - |
| 仿制药原料药及中间体(元) | 375,658,652.70 | 706,138,958.43 | 362,657,620.95 | - | - |
| 高纯溶剂(元) | 33,935,732.06 | - | - | - | - |
| 其他(元) | 1,237,323.79 | -4,055,138.26 | -4,138,262.36 | - | - |
| 毛利率(%) | |||||
| 降血压类原料及中间体(%) | - | - | - | 35.01 | 35.32 |
| 抗凝血类原料药及中间体(%) | - | - | - | 48.06 | 49.35 |
| 降血糖类原料药及中间体(%) | - | - | - | 31.45 | - |
| 降血脂类原料药及中间体(%) | - | - | - | - | - |
| 抗哮喘类原料及中间体(%) | - | - | - | - | - |
| 制剂(%) | 52.23 | 55.61 | 58.19 | - | - |
| CMO(%) | 46.99 | 51.27 | 54.34 | - | - |
| 仿制药原料药及中间体(%) | 27.36 | 31.78 | 32.06 | - | - |
| 高纯溶剂(%) | 16.39 | - | - | - | - |
| 其他(%) | 2.65 | -13.81 | -72.33 | - | - |
| 收入构成(%) | |||||
| 降血压类原料及中间体(%) | - | - | - | 54.62 | 82.46 |
| 抗凝血类原料药及中间体(%) | - | - | - | 10.29 | 17.54 |
| 降血糖类原料药及中间体(%) | - | - | - | 10.37 | - |
| 降血脂类原料药及中间体(%) | - | - | - | 3.79 | - |
| 抗哮喘类原料及中间体(%) | - | - | - | 7.74 | - |
| 制剂(%) | 13.93 | 13.65 | 11.43 | 9.68 | - |
| CMO(%) | 5.17 | 12.80 | 16.02 | - | - |
| 仿制药原料药及中间体(%) | 68.28 | 72.58 | 72.18 | - | - |
| 高纯溶剂(%) | 10.29 | - | - | - | - |
| 其他(%) | 2.32 | 0.96 | 0.37 | 3.50 | - |
| 毛利构成(%) | |||||
| 降血压类原料及中间体(%) | - | - | - | 69.96 | 77.09 |
| 抗凝血类原料药及中间体(%) | - | - | - | 18.10 | 22.91 |
| 降血糖类原料药及中间体(%) | - | - | - | 11.94 | - |
| 降血脂类原料药及中间体(%) | - | - | - | 0.00 | - |
| 抗哮喘类原料及中间体(%) | - | - | - | 0.00 | - |
| 制剂(%) | 24.14 | 20.47 | 17.40 | 0.00 | - |
| CMO(%) | 8.06 | 17.70 | 22.77 | - | - |
| 仿制药原料药及中间体(%) | 61.99 | 62.19 | 60.51 | - | - |
| 高纯溶剂(%) | 5.60 | - | - | - | - |
| 其他(%) | 0.20 | -0.36 | -0.69 | 0.00 | - |